G57321FI
| Organisms | Evidence |
|---|---|
| Fasciola hepatica (liver fluke) | |
| Toxocara canis (dog roundworm) | |
| Echinococcus granulosus | |
| Oryctolagus cuniculus (rabbit) | |
| Ovis aries (sheep) |
| Gene Symbol | Donor | Acceptor | Reducing terminal(Acceptor) | Product | Reducing terminal(Product) | Reference |
|---|---|---|---|---|---|---|
| C1GALT1 | (not applicable) |
|
Ser/Thr |
|
Ser/Thr | |
| ST6GALNAC1 | CMP-Neu5Ac |
|
Ser/Thr |
|
Ser/Thr | |
| ST6GALNAC1 | CMP-Neu5Ac |
|
O-glycan Synthesis |
|
O-glycan Synthesis | |
| B3GNT6 | UDP-GlcNAc |
|
[alpha]-pNP |
|
[alpha]-pNP |
| Gene Symbol | Donor | Acceptor | Reducing terminal(Acceptor) | Product | Reducing terminal(Product) | Reference |
|---|---|---|---|---|---|---|
| C1GALT1 | (not applicable) |
|
Ser/Thr |
|
Ser/Thr | |
| ST6GALNAC4 | CMP-Neu5Ac |
|
benzyl |
|
benzyl | |
| ST6GALNAC1 | CMP-Neu5Ac |
|
Ser/Thr |
|
Ser/Thr | |
| ST6GALNAC1 | CMP-Neu5Ac |
|
O-glycan Synthesis |
|
O-glycan Synthesis | |
| ST6GALNAC1 | CMP-Neu5Ac |
|
[Ala-Thr(*)-Ala]2-7 |
|
[Ala-Thr(*)-Ala]2-7 |
| Gene Symbol | Donor | Acceptor | Reducing terminal(Acceptor) | Reference |
|---|---|---|---|---|
| ST6GALNAC2 | CMP-Neu5Ac |
|
para-nitrophenol | |
| ST6GALNAC1 | CMP-Neu5Ac |
|
[alpha]-Bz | |
| ST6GALNAC3 | CMP-Neu5Ac |
|
Ser/Thr | |
| ST6GALNAC2 | CMP-Neu5Ac |
|
Ser/Thr | |
| ST6GAL2 | CMP-Neu5Ac |
|
para-nitrophenol |
| Pathway Name | Organism |
|---|---|
| Lectin pathway of complement activation | Homo sapiens |
| Lectin pathway of complement activation | Gallus gallus |
| Lectin pathway of complement activation | Canis familiaris |
| Lectin pathway of complement activation | Rattus norvegicus |
| Lectin pathway of complement activation | Sus scrofa |
| Lectin pathway of complement activation | Mus musculus |
| Lectin pathway of complement activation | Xenopus tropicalis |
| PubMed ID | Title | First Author | Publication Date | Source |
|---|---|---|---|---|
| 23744646 | MGL signaling augments TLR2-mediated responses for enhanced IL-10 and TNF-α secretion | van Vliet SJ | 2013 Jun 06 |
|
| 23762286 | CLEC4F Is an Inducible C-Type Lectin in F4/80-Positive Cells and Is Involved in Alpha-Galactosylceramide Presentation in Liver | Yang CY | 2013 Jun 06 |
|
| 23828381 | The level of anti-(GalNAc beta) and anti-para-Forssman disaccharide IgG antibodies in patients with gastrointestinal cancer: relation to survival | Smorodin EP | 2013 Jun |
|
| 23873333 | Neuroprotective effect of 2-(4-methoxyphenyl)ethyl-2-acetamido-2-deoxy-β-d-pyranoside against sodium nitroprusside-induced neurotoxicity in HT22 cells | Chen X | 2013 Jul 20 |
|
| 23692076 | Selection ofEscherichia coliHeat-Labile Toxin (LT) Inhibitors Using Both the GM1-ELISA and the cAMP Vero Cell Assay | Verhelst R | 2013 Jul |
|
| 23184955 | A Single N-Acetylgalactosamine Residue at Threonine 106 Modifies the Dynamics and Structure of Interferon α2a around the Glycosylation Site | Ghasriani H | 2013 Jan 04 |
|
| 23398317 | Defective immunoglobulin A (<scp>IgA</scp>) glycosylation and <scp>IgA</scp> deposits in patients with <scp>IgA</scp> nephropathy | Kolka R | 2013 Feb 11 |
|
| 24131475 | <scp>N</scp>‐acetylgalactosamine exposure of serum <scp>IgA1</scp> was associated with glomerulosclerosis and tubular atrophy/interstitial fibrosis of <scp>IgA</scp> nephropathy patients | Xu L | 2013 Dec 17 |
|
| 24335571 | Extending the Glucosyl Ceramide Cassette Approach: Application in the Total Synthesis of Ganglioside GalNAc-GM1b | Konishi M | 2013 Dec 10 |
|
| 24321012 | Avocado/soybean unsaponifiables: a novel regulator of cutaneous wound healing, modelling and remodelling | Oryan A | 2013 Dec 10 |
|
GlyCosmos is a member of the GlySpace Alliance together with GlyGen and Glycomics@ExPASy.
Supported by JST NBDC Grant Number JPMJND2204
Partly supported by NIH Common Fund Grant #1U01GM125267-01
This work is licensed under Creative Commons Attribution 4.0 International
GlyCosmos Portal v4.4.0
Last updated: December 8, 2025